Since the novel coronavirus disease (COVID-19) was first identified in Wuhan (Huebei Province, China) in December 2019 \[[@CR1]\], it has spread globally resulting in the ongoing 2019--20 coronavirus pandemic \[[@CR2]\] with almost two million confirmed cases, and more than two-hundred countries involved, on April 16th, based on the WHO situation report \[[@CR3]\].

From the second half of February 2020, a rapid and unexpected surge of patients with COVID-19 is posing a serious threat to the Italian National Health Service, especially in Lombardy that, with 62,153 confirmed COVID-19 patients and 11,377 deaths, on Apri1 6th, it is the most hard-hit province in all of Italy during the pandemic \[[@CR4]\].

Our hospital is located in Milan, capital of the Lombardy, and currently it serves as one of the national referral centers for patients with severe COVID-19. To optimize the available healthcare resources, the Lombardy government made a differentiation between elective and non-deferrable procedures from the early period, defining which patients could be treated, namely only emergency and oncologic patients \[[@CR5]\]. Accordingly, most of the interventional oncology procedures are continuing as normal in our center even under such extreme circumstances. The goals are to continue to provide optimal care while reducing infective risk to patients and to staff. Using the appropriate personal protective equipment (PPE) and innovative operating protocols specifically designed for the pandemic \[[@CR6]\], we continue to deploy vascular accesses for chemiotherapy, to perform imaging-guided biopsies, tumor ablations, transarterial radioembolization and chemoembolization therapies. Moreover, we continue to provide palliative procedures such as tunneled peritoneal and pleural catheters, drainage for fluid collections and biliary drainage in pancreas cancer and cholangiocarcinoma, and we also performed every kind of embolization whenever deemed to be necessary on a daily basis.

As cancer patients are a vulnerable population, especially during COVID-19 outbreak, the risks, benefits, and comorbidities of each patient's case must be carefully considered individually.

Although the IR workflow has been reorganized to limit the risk of transmission between patients, and between patients and healthcare workers, we have made no significant changes in our procedure workflows to keep outpatients and inpatients in the same area. However, all patients undergo to reverse transcription polymerase chain reaction (rRT-PCR) test performed on respiratory samples obtained by a nasopharyngeal swab the day before to avoid the risk of cross-contamination. Moreover, we are not keeping patients overnight for observation unless medically necessary.

All staff underwent training for proper donning/doffing of PPE, and we have done rehearsals as well as the real thing. Notably, in our department no incidents between non-infected and infected patients have been documented so far, and there has been no evidence of COVID-19 infection of healthcare workers in the IR service to our knowledge. Additionally, we recently obtained a backup call team to serve as the "clean team" for grabbing supplies and taking over after a procedure on a COVID positive/under investigation patient. Finally, we asked for clearance to test all asymptomatic inpatients but unfortunately our healthcare system cannot currently afford such number of testing bandwidth.
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